Sign in

You're signed outSign in or to get full access.

TG Ganeshan

Director at Performant Healthcare
Board

About TG Ganeshan

TG Ganeshan is Chief Financial Officer of Machinify and became a director of Performant Healthcare, Inc. (PHLT) at the October 21, 2025 merger closing when PHLT was taken private; he was one of two directors of the surviving corporation alongside Machinify CEO David Pierre . He holds a Bachelor’s in Technology (IIT Madras), a Master’s in Engineering (Auburn University), and an MBA (The University of Texas at Austin) with ~20 years of financial leadership spanning healthcare IT, payment integrity, and Fortune 500 roles . Tenure at PHLT: joined the board October 21, 2025; age not disclosed .

Past Roles

OrganizationRoleTenureCommittees/Impact
MachinifyChief Financial Officer2024–present Led finance, capital markets, M&A for healthcare AI platform
InnovaccerChief Financial Officer2022–2024 Oversaw financial strategy, reporting, corporate development
RxSenseChief Financial Officer2021–2022 Built consumer and platform businesses’ finance ops
Optum (UnitedHealth)CFO, Payer Markets; CFO, Payment Integrity2019–2021 Consolidated solutions into high-growth, high-margin group; payment integrity leadership
Equian (acquired by Optum)SVP Finance; VP/Director FP&A2016–2019 Finance leadership through sale to Optum
HiltonSenior Director, FP&A2015–2016 Corporate FP&A leadership
United ParksVP Finance; Sr Director Corporate Planning2009–2015 Corporate planning and finance
SeaWorld, Anheuser-BuschFinancial leadership rolesPrior to 2009 Finance roles across large enterprises

External Roles

EntityRolePublic Company?Notes
Machinify (portfolio company of New Mountain Capital)Chief Financial OfficerNoHealthcare AI/payments; Machinify acquired PHLT in 2025

No public-company directorships disclosed for TG Ganeshan .

Board Governance

  • Board composition changed at merger closing: all legacy PHLT directors resigned; post-merger directors are David Pierre (Machinify CEO) and TG Ganeshan (Machinify CFO) .
  • Independence: As CFO of Machinify and director of PHLT (now a wholly-owned subsidiary of Machinify’s parent), Ganeshan is not independent of the controlling shareholder .
  • Committees: New bylaws permit committees, but no committee assignments disclosed for the two-person board .
  • Attendance: Prior (pre-merger) board met 4 times in 2024 with 100% board and committee attendance by then-serving directors; no attendance disclosure post-merger for Ganeshan .

Fixed Compensation

ComponentAmount/TermsApplicability to TG
Pre-merger independent director cash retainer$40,000 annual; committee retainer $10,000 (Audit), $6,000 (Comp), $5,000 (N&G); chair premiums $20,000 (Audit), $12,000 (Comp), $10,000 (N&G) Not disclosed for TG (joined post-merger; company deregistered)
Pre-merger annual director equityRSU grant with $130,000 grant-date fair value; new director RSU $100,000 vesting ratably 4 years Not disclosed for TG (post-merger)

Note: Following the take-private on Oct 21, 2025, PHLT notified Nasdaq of delisting and intends to terminate registration/reporting; post-merger director compensation terms are not publicly disclosed .

Performance Compensation

No performance-tied director compensation disclosed for TG Ganeshan; pre-merger director equity at PHLT was time-based RSUs, not PSU or performance-linked for directors .

Other Directorships & Interlocks

RelationshipDetailsGovernance Implication
Interlock with controlling parentTG Ganeshan serves as CFO of Machinify; Machinify’s parent acquired PHLT; TG is one of two directors of PHLT post-merger Potential conflict risk; affiliated board control may reduce independence in oversight

Expertise & Qualifications

  • Education: IIT Madras (B.Tech), Auburn University (M.Eng), UT Austin (MBA) .
  • Domain: Payment integrity, payer markets, healthcare IT finance, M&A and capital markets .
  • Executive experience: CFO roles across Innovaccer, RxSense, Optum; finance leadership at Equian .

Equity Ownership

  • No beneficial ownership disclosure for TG in PHLT’s April 2025 proxy (he was not then a director); post-merger, PHLT was delisted and intends to terminate registration, limiting ongoing Section 16 reporting .

Governance Assessment

  • Board effectiveness: Post-merger board reduced to two directors, both affiliated with acquirer/parent, which concentrates control and removes independent oversight compared to pre-merger majority-independent board .
  • Conflicts framework: New certificate and bylaws include an “corporate opportunity” renunciation favoring non-employee officers/directors and stockholders, potentially permitting parent-affiliated fiduciaries to pursue opportunities outside PHLT; also broad indemnification/advancement provisions and permissive interested-director transactions if approved or fair .
  • Investor confidence signal: Transition to private ownership (delisting) ends public governance disclosures and say-on-pay/Section 16 reporting, reducing transparency for public investors; affiliated board suggests heightened related-party oversight needs in private context .

RED FLAGS

  • Affiliated control: Both directors are executives of the acquirer/parent (non-independent) .
  • Corporate opportunity renunciation: May weaken protections against conflicts for non-employee affiliated fiduciaries .
  • Interested director transactions permitted when disclosed/approved or fair; requires strong process to mitigate conflicts .

References to prior governance baseline (context)

  • Pre-merger PHLT director pay structure (cash/equity) and 2024 attendance provide baseline but are not applicable to TG’s post-merger directorship .